Research News

Humans possess a formidable multi-layered defense system that protects us against viral infections. Better understanding of these defenses and the tricks that viruses use to evade them could open novel avenues for treating viral infections and possibly other diseases.

The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate.

Although widely used in manufacturing, robots require much more agility for use in nursing and rehabilitation. With this in mind, an interdisciplinary research team led by Professor James Chang of the Department of Power Mechanical Engineering has recently applied the latest advances in AI, biomechanics, and human-factor engineering to develop a robot that can imitate the meticulous movements of a human hand. Endowed with sharp senses of vision and touch, the robot’s hands are nimble enough to catch a ball and pull out a tissue.

Takeda Pharmaceutical Company Limited announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in previously treated patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) will be presented as a late-breaking oral session at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) on Friday, January 29 SGT.

A new in vitro study done collaboratively by Utah State University and Northwestern University finds Xlear components (grapefruit seed extract and xylitol) significantly eliminates SARS-CoV-2, the virus that causes COVID-19. The imaging research study component was performed at the BioCryo facility of Northwestern University’s NUANCE Center.

Human papillomavirus (HPV) is the most common sexually transmitted infection, with an estimated 79 million Americans currently infected with the virus, according to the Centers for Disease Control and Prevention. If a high-risk HPV infection does not go away, it can lead to the development of a variety of cancers, including 91% of all cervical cancers, 70% of oropharyngeal cancers and cancers of the vulva, vagina, penis and anus.

Head and neck cancer is the sixth most common cancer worldwide, and while effective treatments exist, sadly, the cancer often returns.

Researchers at the University of Cincinnati have tested a new combination therapy in animal models to see if they could find a way to make an already effective treatment even better.

Since they're using a Food and Drug Administration-approved drug to do it, this could help humans sooner than later.

A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment. The research is published in the January 20, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment.

A new potential therapy for COVID-19 developed by researchers at Rush University Medical Center has shown success in preventing the disease’s symptoms in mice.